Skip to content
AASLD Family of Websites: Liver Fellow Network
AASLD.org AASLD Foundation LiverLearning Career Center Journals The Liver Meeting HCV Guidelines
AASLD Logo
AASLD Logo

LFN Main Navigation

  • Topics
    Acute Liver Failure Alcohol-Associated Liver Disease Autoimmune Hepatitis Career Development and Mentorship Cholestatic Liver Disease Complications of Liver Disease and Portal Hypertension Drug-Induced Liver Disease HepMadness Inherited Disorders Liver Anatomy, Development, and Physiology Liver Infections Liver Physiology Liver Related Infections MASLD/MASH Neoplasms of the Liver Pathology Pediatrics Pregnancy-Related Liver Disease Symptoms and Clinical Presentation of Liver Disease and Portal HTN Systemic Conditions with Hepatic Manifestations Transplantation and Surgery Vascular Viral Hepatitis
  • Core Series
    Back to Basics Clinical Pearls Webinars Evidence Corner Pathology Pearls Podcast The Why? Series Tools of the Trade View All Core Series Practice Questions
  • Tweetorials
  • About
  • Core Series
  • Evidence Corner
  • Is Semaglutide The Treatment For NASH We've Been Waiting For?

Is Semaglutide the treatment for NASH we've been waiting for?

April 11, 2021

Jennifer Wang

Share

Copy Link Twitter Facebook

Read the full ground breaking article here: https://www.nejm.org/doi/full/10.1056/NEJMoa2028395

MASLD/MASH

Share

Copy Link Twitter Facebook

Written By:

Jennifer Wang

Related Content

Aldafermin for the Management of Compensated MASH Cirrhosis: the ALPINE-4 Trial

February 9, 2024

Liver stiffness not steatotic liver disease is associated with atrial fibrillation

November 8, 2023

A Stiff Competition: Comparing the MEFIB Index and FAST Score for the Detection of Fibrosis in MASLD

September 22, 2023

AASLD LFN Logo

Follow Us

Disclaimer & Privacy Policy

© 2025 American Association for the Study of Liver Diseases